Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

White House announces steps to boost monkeypox vaccine supply

The FDA has issued emergency authorisation for a dosage technique that would allow more shots of vaccine per vial.

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

With supplies low, FDA authorizes plan to stretch limited monkeypox vaccine doses

With supplies low, FDA authorizes plan to stretch limited monkeypox vaccine doses

The Biden administration is allowing the shot to be given between layers of skin — a method that only requires a fifth of the full dose — in order to increase vaccinations and slow the outbreak.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

US will stretch monkeypox vaccine supply with smaller doses

U.S. health officials are endorsing a new monkeypox vaccination strategy designed to stretch limited supplies by allowing health professionals to vaccinate up to five people — instead of one — with each vial

The Independent UK

Dow Drops Over 100 Points; Verona Pharma Shares Jump

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday.

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.

Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday.

inkl

Read news from The Economist, FT, and more,
with one subscription

Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2

Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2

U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket

Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a stake of 44% in the company in 13D.

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

FDA Can't Stop Harassing Distillers Who Made Hand Sanitizer During the Pandemic

FDA Can't Stop Harassing Distillers Who Made Hand Sanitizer During the Pandemic

After 18 months of dealing with the FDA, some distillers are regretting making hand sanitizers at all.

Plan to axe 91,000 civil servants ‘only possible with cuts to services’

Plan to axe 91,000 civil servants ‘only possible with cuts to services’

Review casts doubt on Boris Johnson’s claim that frontline services would not be harmed

The Guardian - UK

LEXX: Put Your Drinks Up! Four Deals Signed in June

By John Vandermosten, CFA NASDAQ:LEXX READ THE FULL LEXX RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Nature's secret drug stockpile

Some scientists are looking for new drugs in nature rather than synthesizing them in the lab. Here's why

Chicago Sun-Times

In fight against monkeypox, government isn’t learning from past experience

The Biden administration’s response has made key mistakes in handling the emerging threat. We hope this situation serves as a wake-up call to rethink and re-tool emergency response policies and practices.

FDA considering "dose-sparing" approach to increase availability of Jynneos vaccine

Health care providers could use one vial of the vaccine to administer up to five doses without an impact on safety or efficacy.

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga Before The Bell: Should Investors Worry About Tesla's China Sales, Gold Back In Focus, Nio Smartphone Could Soon Be A Reality Other Top Financial Stories Friday, August 5

CNBC International Airlines Prepare For Mayhem Of Summer Travel Season: Report

The next public health emergency

Facing a groundswell of criticism for its sluggish response to monkeypox, the Biden administration declared a public health emergency on Thursday, potentially unlocking millions of dollars toward increasing vaccine availability in the U.S.

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

NYC and San Francisco Prioritize 'First Doses First' for Monkeypox Vaccine. Why Won't the CDC Do the Same?

The CDC and FDA, when confronted with scarce vaccine supply, refuse to learn from their COVID-19 mistakes.

Administration declares monkeypox a public health emergency - Roll Call

The administration declares monkeypox a public health emergency and says it will make it easier to get vaccines to patients.

Monkeypox Is Giving Public Health Agencies a Chance To Prove They've Learned Nothing From COVID

Plus: Schools surveilling students online, Tim Wu leaving the White House, and more...

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

1 … 177 178 179 180

People

John Vandermosten

[ Richard M. ] Burr

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

361,348 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play